Cargando…

Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing

PURPOSE: To discover potential inflammatory biomarkers, which can compare favorably with traditional biomarkers, and their best cut-offs at first admission to predict clinical outcomes (short-term and long-term) and the risk of readmission among acute exacerbations of chronic obstructive pulmonary d...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Shuai, Zhang, Zhijin, Feng, Lin, Liang, Lirong, Tong, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441637/
https://www.ncbi.nlm.nih.gov/pubmed/37608836
http://dx.doi.org/10.2147/COPD.S416869
_version_ 1785093414281281536
author Shao, Shuai
Zhang, Zhijin
Feng, Lin
Liang, Lirong
Tong, Zhaohui
author_facet Shao, Shuai
Zhang, Zhijin
Feng, Lin
Liang, Lirong
Tong, Zhaohui
author_sort Shao, Shuai
collection PubMed
description PURPOSE: To discover potential inflammatory biomarkers, which can compare favorably with traditional biomarkers, and their best cut-offs at first admission to predict clinical outcomes (short-term and long-term) and the risk of readmission among acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients. PATIENTS AND METHODS: Novel inflammatory biomarkers (such as the neutrophil–lymphocyte ratio [NLR], platelet–lymphocyte ratio [PLR], etc.) were compared with traditional biomarkers by Pearson’s correlation test. Logistic regression analysis and receiver operating characteristic (ROC) curves were applied to judge the accuracy of these novel biomarkers to predict in-hospital mortality. RESULTS: Surviving AECOPD patients had lower NLR, PLR, and lymphocyte-to-monocyte ratios than non-survival patients (all P < 0.001). According to Pearson’s correlation test, there was a linear correlation between novel and traditional biomarkers (all P < 0.05). In terms of a single biomarker, the AUC value of NLR was the largest, which was not inferior to C-reactive protein (Z-P = 0.064), and superior to erythrocyte sedimentation rate (Z-P = 0.002) and other novel single inflammatory biomarkers (all Z-P < 0.05). The mortality of patients with NLR ≥ 4.43 was 2.308-fold higher than that of patients with NLR < 4.43. After dividing patients into a higher or lower NLR group, pooled results showed that patients with NLR ≥ 4.43 had a higher rate of treatment failure, intensive care unit admission, longer hospital length of stay, one-year mortality after the index hospitalization, and overall mortality than patients with NLR < 4.43 (all P < 0.001). Patients with NLR ≥ 4.43 were associated with higher and earlier first readmission due to AECOPD than patients with lower NLR. CONCLUSION: NLR was the best to forecast the clinical prognosis and readmission risk among AECOPD patients, which was not inferior to CRP, and the best cut-off value of NLR was 4.43.
format Online
Article
Text
id pubmed-10441637
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104416372023-08-22 Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing Shao, Shuai Zhang, Zhijin Feng, Lin Liang, Lirong Tong, Zhaohui Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: To discover potential inflammatory biomarkers, which can compare favorably with traditional biomarkers, and their best cut-offs at first admission to predict clinical outcomes (short-term and long-term) and the risk of readmission among acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients. PATIENTS AND METHODS: Novel inflammatory biomarkers (such as the neutrophil–lymphocyte ratio [NLR], platelet–lymphocyte ratio [PLR], etc.) were compared with traditional biomarkers by Pearson’s correlation test. Logistic regression analysis and receiver operating characteristic (ROC) curves were applied to judge the accuracy of these novel biomarkers to predict in-hospital mortality. RESULTS: Surviving AECOPD patients had lower NLR, PLR, and lymphocyte-to-monocyte ratios than non-survival patients (all P < 0.001). According to Pearson’s correlation test, there was a linear correlation between novel and traditional biomarkers (all P < 0.05). In terms of a single biomarker, the AUC value of NLR was the largest, which was not inferior to C-reactive protein (Z-P = 0.064), and superior to erythrocyte sedimentation rate (Z-P = 0.002) and other novel single inflammatory biomarkers (all Z-P < 0.05). The mortality of patients with NLR ≥ 4.43 was 2.308-fold higher than that of patients with NLR < 4.43. After dividing patients into a higher or lower NLR group, pooled results showed that patients with NLR ≥ 4.43 had a higher rate of treatment failure, intensive care unit admission, longer hospital length of stay, one-year mortality after the index hospitalization, and overall mortality than patients with NLR < 4.43 (all P < 0.001). Patients with NLR ≥ 4.43 were associated with higher and earlier first readmission due to AECOPD than patients with lower NLR. CONCLUSION: NLR was the best to forecast the clinical prognosis and readmission risk among AECOPD patients, which was not inferior to CRP, and the best cut-off value of NLR was 4.43. Dove 2023-08-17 /pmc/articles/PMC10441637/ /pubmed/37608836 http://dx.doi.org/10.2147/COPD.S416869 Text en © 2023 Shao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shao, Shuai
Zhang, Zhijin
Feng, Lin
Liang, Lirong
Tong, Zhaohui
Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing
title Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing
title_full Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing
title_fullStr Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing
title_full_unstemmed Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing
title_short Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing
title_sort association of blood inflammatory biomarkers with clinical outcomes in patients with aecopd: an 8-year retrospective study in beijing
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441637/
https://www.ncbi.nlm.nih.gov/pubmed/37608836
http://dx.doi.org/10.2147/COPD.S416869
work_keys_str_mv AT shaoshuai associationofbloodinflammatorybiomarkerswithclinicaloutcomesinpatientswithaecopdan8yearretrospectivestudyinbeijing
AT zhangzhijin associationofbloodinflammatorybiomarkerswithclinicaloutcomesinpatientswithaecopdan8yearretrospectivestudyinbeijing
AT fenglin associationofbloodinflammatorybiomarkerswithclinicaloutcomesinpatientswithaecopdan8yearretrospectivestudyinbeijing
AT lianglirong associationofbloodinflammatorybiomarkerswithclinicaloutcomesinpatientswithaecopdan8yearretrospectivestudyinbeijing
AT tongzhaohui associationofbloodinflammatorybiomarkerswithclinicaloutcomesinpatientswithaecopdan8yearretrospectivestudyinbeijing